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Abstract
Background: Recent studies have shown an important reduction of joint overload during locomotion in elderly
women with knee osteoarthritis (OA) after short-term use of minimalist shoes. Our aim is to investigate the chronic
effect of inexpensive and minimalist footwear on the clinical and functional aspects of OA and gait biomechanics
of elderly women with knee OA.
Methods/Design: Fifty-six elderly women with knee OA grade 2 or 3 (Kellgren and Lawrence) are randomized into
blocks and allocated to either the intervention group, which will use flexible, non-heeled shoes— MolecaW—for six
months for at least six hours daily, or the control group, which could not use these shoes. Neither group is undergoing
physical therapy treatment throughout the intervention period. MolecaW is a women’s double canvas, flexible, flat
walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm internal wedge of ethylene vinyl acetate.
Both groups will be followed for six months and will be assessed at baseline condition, after three months, and after six
months (end of intervention). All the assessments will be performed by a physiotherapist that is blind to the group
allocation. The primary outcome is the pain Western Ontario and McMaster Universities Osteoarthritis (WOMAC) score.
The secondary outcomes are global WOMAC score; joint stiffness and disability WOMAC scores; knee pain with a visual
analogue scale; walking distance in the six-minute walk test; Lequesne score; amount and frequency (number of days)
of paracetamol (500 mg) intake over six months; knee adduction moment during gait; global medical assessment
score; and global patient auto-assessment score. At baseline, all patients receive a diary to record the hours of daily use
of the footwear intervention; every two weeks, the same physiotherapist makes phone calls to all patients in order to
verify adherence to treatment. The statistical analysis will be based on intention-to-treat analysis, as well as general
linear models of analysis of variance for repeated measure to detect treatment–time interactions (α= 5%).
Discussion: This is the first randomized, clinical trial protocol to assess the chronic effect of minimalist footwear on the
clinical and functional aspects and gait biomechanics of elderly women with knee osteoarthritis. We expect that the
use of MolecaW shoes for six months will provide pain relief, reduction of the knee adduction moment when walking,
and improve joint function in elderly women with knee OA, and that the treatment, thus, can be considered another
inexpensive and easy-to-use option for conservative OA treatment.
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Background
Osteoarthritis (OA) is the most common musculoskeletal
disease [1,2], mainly affecting joints that suffer constant
overload, such as the knee. As a consequence, routine
daily activities, such as walking and ascending and des-
cending stairs, as well as individual autonomy, may be
compromised.
Knee adduction moment (KAM), usually used to esti-
mate intra-articular overload, has been strongly related
to OA severity [3] and its progression [4,5]—the higher
the intra-articular load, the more severe will be the pro-
gression and functional consequences of the disease.
Great efforts have been made to improve conservative
OA treatments, as, according to the Osteoarthritis Re-
search Society International (OARSI) [6], the actual
available pharmacotherapy is insufficient to control the
clinical manifestations of OA. Surgical procedures have
a high potential to reduce symptoms and improve func-
tion, but they are associated with increased costs, pro-
longed work impairment, and complications. According
to the OARSI, conservative treatments, such as physical
measures that allow improvement of biomechanical
aspects and minimize intra-articular load, particularly
KAM, produce the best evidence of efficacy. Braces for
knee misalignments [7,8] and foot splints [9-13] are
commonly used and frequently recommended as import-
ant interventions for the management of knee OA.
More recently, it has been suggested that foot flexibility
during barefoot gait has the power to reduce the KAM in
individuals with OA [14,15]. However, the opportunity to
perform daily activities barefoot is rare and may be uncom-
fortable, especially for elderly people. There is scientific evi-
dence that modern shoes, including the high-heeled, rigid-
soled shoes commonly used by the majority of women in
their everyday lives [16], generate higher knee moments
and instability during locomotion. This is because modern
shoes provide less flexibility, thereby not reproducing the
degrees of freedom of the foot when it is bare, and causing
progressive damage to knee joints with OA [17].
It has been shown that minimalist shoes that are capable
of simulating barefoot gait reduced KAM in patients with
knee OA [17-19]. More recently, we have shown that the
acute use of an inexpensive, flexible, non-heeled footwear
reduced significantly KAM in elderly women with OA
during gait [20] and descending stairs [21].
Although it is reasonable to suppose a therapeutic ef-
fect of flexible, minimalist, and inexpensive shoes in the
treatment of knee OA, its efficacy in reducing pain and
KAM, as well as recovering musculoskeletal function in
elderly people with knee OA has not been tested yet
through a randomized, controlled trial. If effective, the
use of these inexpensive, minimalist shoes might be part
of a treatment prescription, representing a way of redu-
cing costs associated with OA patients’ treatment.
Our hypothesis is that the use of the intervention foot-
wear by elderly women with knee OA for at least six
hours per day for six months could (i) relieve knee pain;
(ii) improve musculoskeletal function in daily living ac-
tivities; (iii) reduce knee load during gait; and (iv) reduce
the use of medication, and, therefore, could be consid-
ered another inexpensive option for conservative OA
treatment. Our aim is to investigate the therapeutic ef-
fect of inexpensive and minimalist footwear on the clin-
ical and functional aspects of OA and gait biomechanics
in elderly women with knee OA.
Methods/Design
Overview of the research design
A randomized, controlled trial was designed to study the
effects of the shoe intervention on knee OA. Elderly
women diagnosed with knee OA are recruited from hos-
pitals and primary care centres, and are referred to a
physical therapist, who performs the group allocation.
The participants then are referred to another physical
therapist, who performs the initial blind assessment.
All patients allocated to the intervention group (IG)
receive the minimalist footwear on the first day and have
to use it for six months, for at least six hours daily. The
patients allocated to the control group (CG) do not re-
ceive the intervention footwear. All patients are assessed
at baseline condition, after three months, and after six
months (end of intervention). During this period, they
continue to receive routine analgesic medication recom-
mended by the medical staff at the hospital.
Participants and recruitment
This study is currently recruiting patients (study start
date: March 2011).
The eligibility criteria are:
– Women 60 to 80 years of age
– OA diagnosed according the American College of
Rheumatology - ACR [22] criteria
– Radiographic evidence of medial femorotibial
classified as Kellgren–Lawrence [23] grade 2 or 3
– Absence of diagnosed hip and/or ankle OA,
rheumatoid arthritis, or systemic inflammatory
arthritis; asymptomatic OA of both knees
– Knee pain between 3 and 8 on a VAS
– Body mass index (BMI) <35 kg/m2 [17]
– No history of surgical procedure on knee, ankle, or
hip, and no muscle injury in the last six months
– Absence of diagnosed neurological disease [24]
– Leg length discrepancy smaller than 1 cm
– Absence of rigid hallux [12]
– Absence of arthroplasty and/or lower limb orthoses
or indication of lower limb arthroplasty throughout
the intervention period
Trombini-Souza et al. BMC Musculoskeletal Disorders 2012, 13:121 Page 2 of 8
http://www.biomedcentral.com/1471-2474/13/121
– Currently not using the MolecaW or similar shoes
for more than 25 hours per week
– No knee intra-articular steroid or hyaluronic acid
three and six months, respectively, before inclusion
in the study [12]
– Absence of knee instability (verified by clinical
examination to assess the collateral and cruciate
ligaments)
– Absence of dementia or inability to give consistent
information [24]
– Ability to walk independently without an assistive
device for at least six hours a day
– No physical therapy or acupuncture treatment
throughout the intervention period
The use of paracetamol 500 mg every four hours is per-
mitted for both groups for the control of pain, according
to ACR recommendations for OA treatment [25]. NSAIDs
and DMARDs are allowed if initiated at least eight and
four weeks, respectively, prior to randomization, and they
must be used in stable doses throughout the study [12].
The participants are recruited from three settings: (a)
rheumatology clinic medical care located at the Hospital
das Clínicas of the School of Medicine at the University of
São Paulo, (b) orthopaedic ambulatory medical care
located in the University Hospital, and (c) a primary care
centre at the School of Medicine of the University. All po-
tential patients are interviewed by telephone and, when
selected, are assessed, in the rheumatology clinic of the
Hospital das Clínicas of the School of Medicine at the
University of São Paulo, by a rheumatologist who is blind
to the patient’s allocation (Process A). The design and
flowchart of the steps of the protocol are presented in
Figure 1.
After the recruitment, the patients are submitted to
the inclusion and exclusion criteria by the physician
(Process A). All patients are assessed in the biomechan-
ics laboratory (Processes B and C) by a physiotherapist.
This assessment represents the baseline condition. After
three months, both groups are assessed according to
Process B. At the end of the intervention period (after
six months), both groups are assessed according to the
complete protocol (Processes A, B, and C) (Figure 1).
Randomization and blinding
The randomization schedule was prepared using Clinstat
software [26] by an independent researcher who was not
aware of the numeric code for the control and interven-
tion groups. A numeric block randomization sequence is
kept in opaque envelopes.
After the patients’ agreement and assignment to partici-
pate in the research, the allocation into the groups is made
by another independent researcher, who is also unaware
of the codes. Only the physiotherapist responsible for the
clinical trial knows who is receiving the intervention.
The initial and final clinical and medical examinations
(Process A) are carried out by a rheumatologist who is
blind to the patient’s allocation. One physical therapist
(PT 2), who is blind to the treatment allocation, is re-
sponsible for all clinical, functional, and biomechanical
assessments (Processes B and C). Another physical ther-
apist (PT 1) is responsible for group allocation and mon-
itoring the use of the intervention footwear by
telephone. Both physiotherapists are blind to the block
size used in the randomization procedure. The trial sta-
tistician is blind to treatment allocation until the main
treatment analysis has been completed. To ensure that
the researcher physiotherapists remain blind, they will
emphasize to patients that they should not be told
whether or not the patient has received the intervention
footwear.
Protocol assessments
Eligible patients are assessed according to Process A,
which consists of an interview and a clinical examination
to classify the patient’s overall health condition, performed
by the rheumatologist (global medical assessment score
1–5) and by the patient (global patient self-assessment
score). Full-extension anterior–posterior knee radiographs
are used to confirm the OA diagnosis and classification
according to Kellgren–Lawrence criteria [23]. Process A is
performed by a rheumatologist who is blind to the
patient’s allocation. The two overall health condition
assessments are conducted at baseline and at the end of
the intervention period by the same physician.
At baseline, patients from both groups receive a diary
to record the amount, in hours, of MolecaW use, and the
intake of paracetamol tablets (500 mg) on a daily basis.
Every three months, the diaries are collected in order to
account for the MolecaW and painkillers use (Table 1).
Process B consists of an anamnesis specific to knee pain
symptoms at night, while standing, and during locomotion,
using a VAS. Musculoskeletal function is analyzed by a six-
minute walk test [27], the Western Ontario and McMaster
Universities Osteoarthritis questionnaire (WOMAC) [28]
and the algofunctional Lequesne Index of severity of OA
[29]. All patients are assessed according to Process B at
baseline, after three months of intervention, and at the end
of six months intervention, by PT 2. The WOMAC ques-
tionnaire assesses three dimensions: pain, disability, and
joint stiffness in knee OA, and it is refering to 72 hours
prior to the evaluation, using a 24-question, 5-point Likert
protocol. The higher the score, the worse is the condition
[28]. The Lequesne questionnaire assesses pain or discom-
fort, maximum distance walked, and activities of daily liv-
ing, 72 hours prior to the evaluation [29]. The higher the
score, the worse is the condition. The six-minute walk test
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[27] is a practical, simple test that measures the distance
that a patient can quickly walk on a flat, hard, indoor sur-
face in a period of six minutes. This test evaluates the
patient's ability to perform daily living activities. We strictly
followed the American Thoracic Society guidelines when
conducting this test [27].
Process C consists of a biomechanical gait analysis; the
inverse dynamic approach is employed to calculate KAM.
Patients of both groups are assessed at the baseline and at
the end of six months. We use three-dimensional dis-
placement of passive reflective markers (20 mm in diam-
eter), tracked with six infrared cameras (OptiTrack FLEX:
V100; Natural Point, Corvallis, OR, USA) [20] and ground
reaction forces acquired by a force plate (AMTI OR 6–7
1000, Watertown, MA, USA) embedded in the centre of a
10-meter walkway. The reflective markers are placed on
Figure 1 Flowchart of the protocol steps.
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the subject using a standard Cleveland Clinic marker set
[30]. Extra markers are placed bilaterally at the medial
knee joint line, medial malleolus, and first metatarsal joint
for the static standing trial, in order to determine relative
joint centres of rotation for the knee, ankle, and longitu-
dinal axis of the foot. These extra markers are removed in
the gait trial. In addition, two sets of technique clusters
are placed in the lateral thigh and over the shank. Marker
placement is performed by the same physiotherapist who
performs the blind assessment (Processes B and C). We
evaluate the limb correspondent to the symptomatic knee
in subjects with unilateral OA and the most symptomatic
knee in subjects with bilateral OA [17,18].
The laboratory coordinate system is established at one
corner of the force plate, and all initial calculations are
based on this coordinate system. Each lower limb segment
(foot, shank, and thigh), based on surface markers, is mod-
elled as a rigid body with a local coordinate system that
coincides with the anatomical axes. Translations and rota-
tions of each segment are reported relative to neutral posi-
tions defined during the initial standing static trial. The
inertial properties are based on Dempster’s standard re-
gression equations. The moment of inertia and location of
centre of mass are computed assuming the thigh and
shank segments as a cylindrical geometric shape. The knee
is examined as a bicondylar type joint with biplane move-
ments; flexion/extension, adduction/abduction (in smaller
range of motion) andmedial and lateral axial rotation [31].
Force and kinematic data acquisition are synchronized
and sampled by an A/D card (AMTI, DT 3002, 12 bits)
at 100 Hz. We use the Visual3D software (C-motion,
Kingston, ON, Canada) and a custom-written Matlab
function (MathWorks, Natick, MA, USA) to perform all
mathematical procedures.
Outcome measures
The primary outcome measure is the pain WOMAC
score (Table 2), based on the OARSI task force [32].
The secondary outcomes are: total WOMAC score;
joint stiffness and disability WOMAC subscale scores;
knee pain symptom on movement, at rest, and at night
with a VAS; walking distance in the six-minute walk test;
Lequesne score; intake of paracetamol (500 gm) (number
of days and quantity) over six months; knee load during
gait; global medical assessment score; and global patient
self-assessment score (Table 2).
Intervention
The intervention is based on the daily use of the inter-
vention footwear—MolecaW—for six months, for at least
42 hours per week (approximately six hours a day, seven
days a week).
MolecaW footwear (Calçados Beira Rio S.A., Novo Ham-
burgo, RS, Brazil) is a low-cost women’s double canvas,
flexible, flat, walking shoe without heels, with a 5-mm anti-
slip rubber sole and a 3-mm internal wedge of ethylene
vinyl acetate (Figure 2). Its mean weight is 0.172±0.019 kg,
ranging from 0.091 to 0.182 kg depending on the shoe size.
This minimalist footwear has been produced on a large
scale in Brazil since 1986 and is commonly worn by the
Table 1 Diary of intervention shoe use and Paracetamol intake
NAME:________________________________________________ _____MONTH – First day: _____/_____/_____ Final day: _____/_____/_____
DATE / / / / / / / / / / / / / / /
Hours of use
Amount of tablets (paracetamol)
DATE / / / / / / / / / / / / / / /
Hours of use
Amount of tablets (paracetamol)
INSTRUCTION: At the end of every day, you must write down the total amount of hours that you used the Moleca and the number of paracetamol tablets taken
(take only if you feel knee pain).
Table 2 Outcome measures
Primary Outcome Measurement
Pain subscale WOMAC osteoarthritis score
Secondary Outcomes
- Stiffness and
disability subscale
- WOMAC osteoarthritis score
- Knee pain - Visual Analogue Scale (0–10 cm)
- Function and
progression of OA
- Lequesne’s algofunctional
questionnaire score
- Six-minute walk
test result
- Distance (m)
- Paracetamol
(500 mg) intake
- Days and amount of paracetamol
ingested over six months
- Knee load during
gait
- Knee adduction moment (%body
weight/height) by inverse dynamics
during gait
- Global medical
assessment
- Ordinal scale (1-much worse, 2-slightly
worse, 3-no change, 4-slightly better,
5-much better)
- Global patient’s
self-assessment
- Ordinal scale (1-much worse, 2-slightly
worse, 3-no change, 4-slightly better,
5-much better)
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elderly of lower social classes. We bought all the pairs of
MolecaW shoes for the patients. For hygiene reasons, we
ask the patients to wear thin cotton or silk socks with the
footwear.
Every two weeks, the same physiotherapist (PT 1)
makes phone calls to the IG patients in order to verify
adherence to the treatment and the correct filling out of
the diary. After three and six months of intervention,
the patients in the IG group have their pair of MolecaW
shoes photographed and checked for natural wear of the
shoe with its daily use. If there are tears or holes in the
shoes, they are replaced with a new pair.
During the intervention period, patients from the CG
should not wear MolecaW or similar minimalist shoes,
but they continue to receive their recommended health
care and painkiller medication at the hospital. At the
end of the intervention period, all CG patients also re-
ceive a free pair of MolecaW shoes.
Sample size and statistical analysis
The sample size calculation was made based on the
achievement of a minimal clinically meaningful improve-
ment [33] using an effect size of 0.30 (moderate effect
size), considering the pain WOMAC score as primary out-
come measure. We took the SD estimates from a study we
had previously completed, in which we recruited a similar
patient cohort [18]. A sample size of 56 patients is needed
to provide 80% power to detect a moderate effect differ-
ence between the highest and lowest group pain means,
assuming an alpha level of 0.05 and a statistical design of
F test of repeated measures (between and within effects),
and assuming a 10% loss to follow-up. Twenty-eight
patients will be allocated to each group. The statistical
analysis will be based on intention-to-treat analysis, and
general linear models of analysis of variance for repeated
measure will be used to detect treatment–time interactions
(α=5%). The outcome measures will be compared among
baseline, three months, and six months, and between
groups. The expected treatment effect is a difference of 20%
between groups in the percentage of patients improved,
using the WOMAC score [34].
Ethics and data security
This trial was approved by the Ethics Committee of the
School of Medicine of the University of São Paulo (# 0810/
10). All patients are asked to provide written, informed
consent prior to randomization, using standard forms. Data
access and storage are kept with National Health and Med-
ical Research Council guidelines, as approved. This trial is
registered in Clinical Trials (a service of U.S. National Insti-
tutes of Health) with the number NCT01342458.
Discussion
Based on our previous and promising results of an effi-
cient reduction of knee joint load in women both with
and without OA during activities of daily living using
the same footwear [20,21], we propose a conservative
and low-cost intervention for these patients. It is import-
ant to emphasize that this type of footwear has been
available in our country on a large scale since the 1980s,
and it is widely used for the comfort it provides. There-
fore, it is expected that adherence to this form of ther-
apy will be greater and easier than the use of knee
braces [7,8] and subtalar strapping splints [9].
To our knowledge, this is the first randomized, clinical
trial that aims at treatment for knee OA by means of in-
expensive and minimalist footwear. We propose a flex-
ible shoe as an intervention that mimics barefoot gait
and, consequently, may reduce knees load in elderly
women with chronic OA. If effective, at the end of the
intervention, we expect to observe knee pain relief, im-
provement of musculoskeletal function in daily living ac-
tivities, and reduced intake of analgesics by elderly
women with knee OA.
In contrast to previous studies that include different
levels of radiographic OA involvement [35-37], we
emphasize herein the importance of selecting a more
homogeneous group of patients, based on the Kellgren–
Lawrence radiographic scale (grades 2 and 3). In fact,
heterogeneity among radiographic involvement within
the intervention and control groups could be associated
with a variety of levels of symptoms and therefore, dif-
ferent effectiveness of the proposed intervention. Fur-
thermore, only patients with pain in the 3–8 range of
the VAS are included, in order to eliminate participants
who probably will not achieve further improvement, as
well as participants with more severe degrees of the dis-
ease, who probably will be less responsive.
Another issue taken into account was the higher BMI
limit. In our study, the maximum permitted BMI was
Figure 2 MolecaW shoes for women, made of double canvas,
with flexible rubber soles and without heels.
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35 km/m2. Although the KAM was normalized by a per-
centage of the subject’s body weight and height to allow
for comparisons among subjects, high concentrations of
fat in some parts of the body, such as the thigh and the
pelvis, can provoke many movement artefacts and then
interfere in KAM calculation.
In this study, we highlight the crucial importance of
periodic monitoring of the use of the intervention foot-
wear and medication intake. One physical therapist has
telephone contact with the participants every two weeks,
to know about the use and the physical state of the
intervention shoes, the filling out of the diary, and any
issues related to the OA or medication intake. Usually,
this practice is not observed in other studies [38,39] and
may have interfered in their results. In these cited stud-
ies, the participants were asked only to record and re-
turn, via a packet sent in the mail, the number of hours
they wore the study shoes per day, without monitoring
regularly their usage.
Taking into account the period of daily use, we stipu-
lated that the MolecaW shoe should be utilized for at
least six hours daily, corresponding to 75% of the hours
spent in usual daily activities. To determine this time
usage, we took into account the analysis of van Raaij
et al. [37], who determined the ideal timing of daily
splint use, including insoles and braces, for knee OA.
However, these same authors consider that the optimum
amount of time for the use of the studied shoe cannot
be categorically determined. Patients that have previ-
ously used MolecaW shoes for at least 25 hours weekly
are excluded from this study in order to avoid bias in
the results analysis.
The primary outcome measure is the pain WOMAC
score, based on the OARSI task force [32]. This primary
outcome, obtained by means of the WOMAC question-
naire, is widely used in the evaluation of knee OA. It is a
valid, reliable, and responsive outcome measure that has
been used as a main outcome in other randomized clin-
ical trials in knee OA [39,40], and it is more sensitive to
treatment changes than other WOMAC dimensions
[28]. We used a linguistically validated Portuguese ques-
tionnaire [41].
Of our many secondary outcomes, we emphasize KAM.
This variable is very important in representing knee loads
during locomotion. In contrast to the other variables,
which consist of subjective aspects, such as pain, stiffness,
and disability, KAM is not subject to this drawback.
We expect that this trial will provide additional insights
regarding the effectiveness of minimalist and inexpensive
footwear intervention in the improvement of clinical and
functional aspects of OA and gait biomechanics in elderly
woman with knee OA. Moreover, it may be indicated as
another inexpensive option for conservative treatment of
elderly women with knee OA.
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